Istituto Nazionale Neurologico Besta, Unit of Neuro-Oncology and Gene Therapy, Milan, Italy (Author for correspondence).
Cytotechnology. 2003 Mar;41(2-3):93-101. doi: 10.1023/A:1024818621377.
Stem cells of different origin are under careful scrutiny as potential new tools for the treatment of several neurological diseases. The major focus of these reaserches have been neurodegenerative disorders, such as Huntington Chorea or Parkinson Disease (Shihabuddin et al., 1999). More recently attention has been devoted to their use for brain repair after stroke (Savitz et al., 2002). In this review we will focus on the potential of stem cell treatments for glioblastoma multiforme (Holland, 2000), the most aggressive primary brain tumor, and globoid cell leukodystrophy (Krabbe disease), a metabolic disorder of the white matter (Berger et al., 2001). These two diseases may offer a paradigm of what the stem cell approach may offer in term of treatment, alone or in combination with other therapeutic approaches. Two kinds of stem cells will be consideredhere: neural stem cells and hematopoietic stem cells, both obtained after birth. The review will focus on experimental models, with an eye on clinical perspectives.
不同来源的干细胞正被作为治疗几种神经疾病的潜在新工具而受到仔细研究。这些研究的主要焦点是神经退行性疾病，如亨廷顿舞蹈病或帕金森病（Shihabuddin 等人，1999 年）。最近，人们越来越关注它们在中风后大脑修复中的应用（Savitz 等人，2002 年）。在这篇综述中，我们将重点关注干细胞治疗多形性胶质母细胞瘤（Holland，2000 年）的潜力，这是最具侵袭性的原发性脑肿瘤，以及球形体白质营养不良（Krabbe 病），这是一种白质的代谢紊乱（Berger 等人，2001 年）。这两种疾病可能为干细胞治疗方法在单独或与其他治疗方法联合治疗方面提供了一个范例。这里将考虑两种类型的干细胞：神经干细胞和造血干细胞，均在出生后获得。综述将重点关注实验模型，并着眼于临床前景。
